XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.24.3

Fair Value Measurements | 9 Months Ended
--- | ---
Sep. 30, 2024
Fair Value Disclosures [Abstract] |
Fair Value Measurements | 15.FAIR VALUE MEASUREMENTS The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis in periods subsequent to their initial measurement. These tiers include: Level 1, defined as quoted market prices in active markets for identical assets or liabilities; Level 2, defined as inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, model-based valuation techniques for which all significant assumptions are observable in the market, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and Level 3, defined as unobservable inputs that are not corroborated by market data. The Company’s financial assets and liabilities recorded at fair value on a recurring basis include derivative instruments and restricted cash and investments. At September 30, 2024 and December 31, 2023, the Company’s derivative instruments included pay-fixed, receive-variable interest rate swaps. The Company’s interest rate swaps are recorded at their estimated fair values based on quotes received from financial institutions that trade these contracts. The Company verifies the reasonableness of these quotes using similar quotes from another financial institution as of each date for which financial statements are prepared. For the Company’s interest rate swaps, the Company also considers the Company’s creditworthiness in its determination of the fair value measurement of these instruments in a net liability position and the counterparties’ creditworthiness in its determination of the fair value measurement of these instruments in a net asset position. The Company’s restricted cash is valued at quoted market prices in active markets for identical assets, which the Company receives from the financial institutions that hold such investments on its behalf. The Company’s restricted cash measured at fair value is invested primarily in money market accounts and bank time deposits. The Company’s restricted investments are valued at quoted market prices in active markets for similar assets, which the Company receives from the financial institutions that hold such investments on its behalf. The Company’s restricted investments measured at fair value are invested primarily in U.S. government, agency securities and Canadian bankers’ acceptance notes. The Company’s assets and liabilities measured at fair value on a recurring basis at September 30, 2024 and December 31, 2023, were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value Measurement at September 30, 2024 Using
​ |  | ​ | ​ |  | Quoted Prices in |  | Significant |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Active Markets | ​ | Other | ​ | Significant
​ | ​ | ​ | ​ | ​ | for Identical | ​ | Observable | ​ | Unobservable
​ | ​ | ​ | ​ | ​ | Assets | ​ | Inputs | ​ | Inputs
​ | ​ | Total | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Interest rate swap derivative instruments – net asset position | ​ | $ | 11,396 | ​ | $ | — | ​ | $ | 11,396 | ​ | $ | —
Restricted cash | ​ | $ | 123,243 | ​ | $ | 123,243 | ​ | $ | — | ​ | $ | —
Restricted investments | ​ | $ | 78,963 | ​ | $ | — | ​ | $ | 78,963 | ​ | $ | —
Contingent consideration | ​ | $ | (82,599) | ​ | $ | — | ​ | $ | — | ​ | $ | (82,599)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fair Value Measurement at December 31, 2023 Using
​ |  | ​ | ​ |  | Quoted Prices in |  | Significant |  | ​ | ​
​ | ​ | ​ | ​ | ​ | Active Markets | ​ | Other | ​ | Significant
​ | ​ | ​ | ​ | ​ | for Identical | ​ | Observable | ​ | Unobservable
​ | ​ | ​ | ​ | ​ | Assets | ​ | Inputs | ​ | Inputs
​ | ​ | Total | ​ | (Level 1) | ​ | (Level 2) | ​ | (Level 3)
Interest rate swap derivative instruments – net asset position | ​ | $ | 22,787 | ​ | $ | — | ​ | $ | 22,787 | ​ | $ | —
Restricted cash | ​ | $ | 105,639 | ​ | $ | 105,639 | ​ | $ | — | ​ | $ | —
Restricted investments | ​ | $ | 70,658 | ​ | $ | — | ​ | $ | 70,658 | ​ | $ | —
Contingent consideration | ​ | $ | (115,030) | ​ | $ | — | ​ | $ | — | ​ | $ | (115,030)
​ ​ The following table summarizes the changes in the fair value for Level 3 liabilities related to contingent consideration for the nine months ended September 30, 2024 and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended September 30, | ​
​ |  | 2024 |  | 2023 |
Beginning balance | ​ | $ | 115,030 | ​ | $ | 81,415 | ​
Contingent consideration recorded at acquisition date | ​ |  | 23,926 | ​ |  | 13,350 | ​
Payment of contingent consideration recorded at acquisition date | ​ |  | (26,625) | ​ |  | (4,255) | ​
Payment of contingent consideration recorded in earnings | ​ |  | (35,035) | ​ |  | — | ​
Adjustments to contingent consideration | ​ | ​ | — | ​ |  | 30,367 | ​
Interest accretion expense | ​ |  | 5,303 | ​ |  | 1,131 | ​
Ending balance | ​ | $ | 82,599 | ​ | $ | 122,008 | ​
​ ​

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details
Name: | us-gaap_FairValueMeasurementInputsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration